Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 124 results
Filters: Author is Kelesidis, Theodoros  [Clear All Filters]
Found 124 results.

Adult

Kelesidis T, Kendall MA, Yang OO, Hodis H, Currier JS. "Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study." AIDS Res. Hum. Retroviruses. 2013;29(6):938-48.
Kelesidis T, Tran TTien T, Stein JH, et al. "Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s." Clin. Infect. Dis.. 2015;61(4):651-60.
Kelesidis T, Kendall MA, Danoff A, Aberg JA, Currier JS, Schmidt AMarie. "Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus: ACTG NWCS332." Medicine (Baltimore). 2018;97(22):e10955.
Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. "Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection." J. Infect. Dis.. 2012;206(10):1558-67.
Kelesidis T, Jackson N, McComsey GA, et al. "Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection." AIDS. 2016;30(17):2625-2633.
Brown TT, Moser C, Currier JS, et al. "Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir." J. Infect. Dis.. 2015;212(8):1241-9.
Kelesidis T, Yang OO, Kendall MA, Hodis HN, Currier JS. "Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults." Lipids Health Dis. 2013;12:23.

Pages